Stock listing

REPL Stock Price, News, Filings & Events — Replimune Group, Inc.

Selected listing: REPL · NASDAQ · USD · US

This page tracks Replimune Group, Inc.'s REPL:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following REPL:NASDAQ. REPL:NASDAQ is the stock-level entry point for investors researching Replimune Group, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Replimune Group, Inc. is a public company traded under the ticker REPL in the American market. It has a market capitalization of approximately $814.45 million. The company focuses on developing innovative therapies for cancer treatment.

REPL:NASDAQUSDUSUpdated September 11, 2026
Replimune Group, Inc. logo
Ticker
REPL:NASDAQ
Asset type
Stock
Market cap
$1.22B
Sector
Health Technology
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

Replimune Group, Inc. REPL:NASDAQ stock context

This page tracks Replimune Group, Inc.'s REPL:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following REPL:NASDAQ. REPL:NASDAQ is the stock-level entry point for investors researching Replimune Group, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Replimune Group, Inc. is a public company traded under the ticker REPL in the American market. It has a market capitalization of approximately $814.45 million. The company focuses on developing innovative therapies for cancer treatment.

Latest news from Replimune Group, Inc.

All Replimune Group, Inc. news →

Replimune Group, Inc. earnings calls

Research Replimune Group, Inc.

Alternate listings